Performance-Enhancing Drugs (PEDs): Medical and Ethical Frontiers
The discussion around PEDs in 2026 has expanded from sports scandals to "Longevity and Wellness" medicine. While anabolic steroids and HGH remain banned in competitive sports due to severe risks like cardiomegaly and hepatic tumors, a new class of drugs called SARMs (Selective Androgen Receptor Modulators) has emerged.
SARMs are designed to provide the muscle-building benefits of steroids without the same level of impact on the prostate or secondary sexual characteristics, though they are not yet fully FDA-approved for human use. In the clinical world, "Performance Enhancement" is being reframed as Sarcopenia Prevention in the elderly, where low-dose testosterone and myostatin inhibitors are being studied to help aging populations maintain mobility and prevent falls.